Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Total Liabilities (2017 - 2025)

Historic Total Liabilities for Cue Biopharma (CUE) over the last 9 years, with Q3 2025 value amounting to $18.4 million.

  • Cue Biopharma's Total Liabilities fell 537.96% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.4 million, marking a year-over-year decrease of 537.96%. This contributed to the annual value of $14.7 million for FY2024, which is 3989.77% down from last year.
  • According to the latest figures from Q3 2025, Cue Biopharma's Total Liabilities is $18.4 million, which was down 537.96% from $22.5 million recorded in Q2 2025.
  • In the past 5 years, Cue Biopharma's Total Liabilities ranged from a high of $27.2 million in Q2 2023 and a low of $14.7 million during Q4 2024
  • Its 5-year average for Total Liabilities is $21.6 million, with a median of $22.5 million in 2025.
  • Its Total Liabilities has fluctuated over the past 5 years, first skyrocketed by 6630.41% in 2022, then crashed by 3989.77% in 2024.
  • Cue Biopharma's Total Liabilities (Quarter) stood at $17.9 million in 2021, then soared by 42.95% to $25.6 million in 2022, then dropped by 4.52% to $24.4 million in 2023, then crashed by 39.9% to $14.7 million in 2024, then increased by 25.22% to $18.4 million in 2025.
  • Its Total Liabilities was $18.4 million in Q3 2025, compared to $22.5 million in Q2 2025 and $15.7 million in Q1 2025.